Endologix (ELGX) is Initiated by Leerink Partners to Mkt Perform

Endologix (ELGX) was Initiated by Leerink Partners to “Mkt Perform”. Leerink Partners advised their investors in a research report released on Sep 6, 2016.

Many Wall Street Analysts have commented on Endologix. Shares were Downgraded by RBC Capital Mkts on Aug 3, 2016 to ” Sector Perform” and Lowered the Price Target to $ 12 from a previous price target of $17 .Company shares were Reiterated by RBC Capital Mkts on Jun 13, 2016 to “Outperform”, Firm has raised the Price Target to $ 17 from a previous price target of $15 .

On the company’s financial health, Endologix reported $-0.20 EPS for the quarter, based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus estimate of $-0.20. The company had revenue of $50.97 million for the quarter, compared to analysts expectations of $46.21 million. The company’s revenue was up 29.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.18 EPS.

Endologix opened for trading at $12.16 and hit $12.3 on the upside on Thursday, eventually ending the session at $12.22, with a gain of 0.49% or 0.06 points. The heightened volatility saw the trading volume jump to 6,54,900 shares. Company has a market cap of $1,007 M.

In a different news, on Aug 22, 2016, Jose A. Lima (VP-Quality) sold 4,710 shares at $11.68 per share price. According to the SEC, on Aug 8, 2016, Michael V. Chobotov (Chief Technology Officer) sold 14,000 shares at $12.40 per share price. On Jun 6, 2016, Gregory D Waller (director) sold 7,800 shares at $12.86 per share price, according to the Form-4 filing with the securities and exchange commission.

Endologix Inc. is engaged in developing manufacturing marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS) its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Company’s EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.


Leave a Reply

Endologix - Is it time to Sell?

Top Brokerage Firms are advising their investors on Endologix. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.